{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:39:27Z","timestamp":1788838767875,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.11.062","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T18:49:51Z","timestamp":1638470991000},"page":"316-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009\u20132017"],"prefix":"10.1016","volume":"40","author":[{"given":"Cintia","family":"Mu\u00f1oz-Quiles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"L\u00f3pez-Lacort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edez-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallivana","family":"Rodrigo-Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Orrico-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2021.11.062_b0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2021.11.062_b0010","first-page":"A4140","article-title":"Long-term quality of life effects of genital warts - a follow-up study","volume":"57","author":"Mortensen","year":"2010","journal-title":"Dan Med Bull"},{"issue":"13","key":"10.1016\/j.vaccine.2021.11.062_b0015","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1186\/1471-2458-13-1065","article-title":"Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK","volume":"12","author":"Dominiak-Felden","year":"2013","journal-title":"Bmc Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.062_b0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/sti.2007.029512","article-title":"Estimation of the impact of genital warts on health-related quality of life","volume":"84","author":"Woodhall","year":"2008","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2021.11.062_b0025","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00129-017-4123-2","article-title":"Human papillomavirus vaccines. Efficacy and adverse effects","volume":"50","author":"Eggersmann","year":"2017","journal-title":"Gynakologe"},{"issue":"5","key":"10.1016\/j.vaccine.2021.11.062_b0030","first-page":"CD009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9686","key":"10.1016\/j.vaccine.2021.11.062_b0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.11.062_b0040","doi-asserted-by":"crossref","unstructured":"Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.","DOI":"10.1056\/NEJMoa061741"},{"issue":"10197","key":"10.1016\/j.vaccine.2021.11.062_b0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.11.062_b0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2021.11.062_b0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2352-4642(18)30220-7","article-title":"Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study","volume":"2","author":"Silverberg","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2021.11.062_b0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.vaccine.2021.11.062_b0065","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV Vaccination and the Risk of Invasive Cervical Cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.11.062_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djab080","article-title":"Real-world Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer","author":"Kjaer","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2021.11.062_b0075","unstructured":"UNICEF Supply Division. Human papillomavirus vaccine supply and demand update. 2018. https:\/\/www.unicef.org\/supply\/reports\/human-papillomavirus-hpv-vaccine-supply-and-demand-update.. Access date April 28, 2021"},{"key":"10.1016\/j.vaccine.2021.11.062_b0080","doi-asserted-by":"crossref","unstructured":"Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.","DOI":"10.1136\/bmj.f2032"},{"key":"10.1016\/j.vaccine.2021.11.062_b0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/OLQ.0b013e31827bd66b","article-title":"Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program","volume":"40","author":"Baandrup","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.11.062_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2361-5","article-title":"Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study","volume":"17","author":"Cocchio","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2021.11.062_b0095","doi-asserted-by":"crossref","first-page":"e0132404","DOI":"10.1371\/journal.pone.0132404","article-title":"Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study","volume":"10","author":"Dominiak-Felden","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.11.062_b0100","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12879-017-2663-7","article-title":"Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data","volume":"17","author":"Th\u00f6ne","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.11.062_b0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2105\/AJPH.2017.304119","article-title":"Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006\u20132014","volume":"108","author":"Flagg","year":"2018","journal-title":"Am J Public Health"},{"issue":"10222","key":"10.1016\/j.vaccine.2021.11.062_b0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0140-6736(19)33153-8","article-title":"Population-level impact of human papillomavirus vaccination","volume":"395","author":"Brotons","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.11.062_b0115","doi-asserted-by":"crossref","first-page":"106166","DOI":"10.1016\/j.ypmed.2020.106166","article-title":"Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women","volume":"138","author":"Brotons","year":"2020","journal-title":"Prev Med"},{"issue":"25","key":"10.1016\/j.vaccine.2021.11.062_b0120","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.vaccine.2017.04.080","article-title":"Effectiveness of HPV vaccines against genital warts in women from Valencia,Spain","volume":"35","author":"Navarro-Illana","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.062_b0125","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/ije\/dyz266","article-title":"Data resource profile: the Valencia health system integrated database (VID)","volume":"49","author":"Garcia-Sempere","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"39","key":"10.1016\/j.vaccine.2021.11.062_b0130","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1016\/j.vaccine.2016.08.020","article-title":"Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment","volume":"34","author":"Guerra","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.11.062_b0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/1471-2334-13-463","article-title":"Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)","volume":"13","author":"Morant-Talamante","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.11.062_b0140","unstructured":"Generalitat Valenciana CdSUiSP. Hist\u00f3rico de calendarios de vacunaci\u00f3n infantil en la Comunitat Valenciana (1992-2015). http:\/\/www.sp.san.gva.es\/DgspPortal\/docs\/HistoricoCalendariosVacunacionInfantil(vf).pdf Access date 2021 April, 22."},{"key":"10.1016\/j.vaccine.2021.11.062_b0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pvr.2017.06.002","article-title":"HPV vaccination of immunocompromised hosts","volume":"4","author":"Garland","year":"2017","journal-title":"Papillomavirus Res"},{"issue":"13","key":"10.1016\/j.vaccine.2021.11.062_b0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2334-13-39","article-title":"Systematic review of the incidence and prevalence of genital warts","volume":"25","author":"Patel","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.11.062_b0155","doi-asserted-by":"crossref","first-page":"100177","DOI":"10.1016\/j.pvr.2019.100177","article-title":"Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis","volume":"8","author":"Brotherton","year":"2019","journal-title":"Papillomavirus Res"},{"issue":"32","key":"10.1016\/j.vaccine.2021.11.062_b0160","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs","volume":"36","author":"Markowitz","year":"2018","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2021.11.062_b0165","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2018.02.087","article-title":"Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study","volume":"36","author":"Sankaranarayanan","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.11.062_b0170","doi-asserted-by":"crossref","first-page":"200216","DOI":"10.1016\/j.tvr.2021.200216","article-title":"Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?","volume":"11","author":"Smith","year":"2021","journal-title":"Tumour Virus Res"},{"key":"10.1016\/j.vaccine.2021.11.062_b0175","unstructured":"WHO. Accelerating cervical cancer elimination. Report by the Director General. http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/EB144\/B144_28-en.pdf 2018."},{"issue":"2","key":"10.1016\/j.vaccine.2021.11.062_b0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/sextrans-2016-052626","article-title":"Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16\/18) vaccination programme in England: an ecological analysis","volume":"93","author":"Canvin","year":"2017","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2021.11.062_b0185","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/infdis\/jit361","article-title":"Declining genital Warts in young women in england associated with HPV 16\/18 vaccination: an ecological study","volume":"208","author":"Howell-Jones","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2021.11.062_b0190","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/sextrans-2018-053751","article-title":"Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017","volume":"95","author":"Checchi","year":"2019","journal-title":"Sex Transm Infect"},{"issue":"46","key":"10.1016\/j.vaccine.2021.11.062_b0195","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1016\/j.vaccine.2015.09.071","article-title":"Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: Population-based cross-sectional survey of Czech women aged 16 to 40 years","volume":"33","author":"Petr\u00e1\u0161","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.11.062_b0200","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1080\/21645515.2015.1049787","article-title":"Intussusception following rotavirus vaccination in the valencia Region, Spain","volume":"11","author":"P\u00e9rez-Vilar","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"15","key":"10.1016\/j.vaccine.2021.11.062_b0205","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12879-015-0811-5","article-title":"Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia Region, Spain","volume":"25","author":"Perez-Vilar","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.11.062_b0210","unstructured":"Fundaci\u00f3n IDIS. https:\/\/www.fundacionidis.com\/informes-ccaa\/valencia. Access date 2021 October, 10."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2101536X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2101536X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:14Z","timestamp":1759403174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2101536X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X2101536X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009\u20132017","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}